A Gene Expression Signature Associated with "K-Ras Addiction" Reveals Regulators of EMT and Tumor Cell Survival

被引:660
作者
Singh, Anurag [1 ,2 ]
Greninger, Patricia [1 ,2 ]
Rhodes, Daniel [3 ,4 ]
Koopman, Louise [5 ]
Violette, Sheila [6 ]
Bardeesy, Nabeel [1 ,2 ]
Settleman, Jeff [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA
[2] Harvard Univ, Sch Med, Charlestown, MA 02129 USA
[3] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Sch Med, Dept Bioinformat, Ann Arbor, MI 48109 USA
[5] Biogen Idec Inc, Dept Discovery Oncol, Cambridge, MA 02142 USA
[6] Stromedix Inc, Cambridge, MA 02141 USA
关键词
MESENCHYMAL TRANSITION; PANCREATIC ADENOCARCINOMA; TYROSINE KINASE; LUNG-CANCER; SENSITIVITY; AMPLIFICATION; PROGRESSION; ACTIVATION; BIOLOGY; GENOME;
D O I
10.1016/j.ccr.2009.03.022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
K-ras mutations occur frequently in epithelial cancers. Using short hairpin RNAs to deplete K-Ras in lung and pancreatic cancer cell lines harboring K-ras mutations, two classes were identified-lines that do or do not require K-Ras to maintain viability. Comparing these two classes of cancer cells revealed a gene expression signature in K-Ras-dependent cells, associated with a well-differentiated epithelial phenotype, which was also seen in primary tumors. Several of these genes encode pharmacologically tractable proteins, such as Syk and Ron kinases. and integrin beta 6, depletion of which induces epithelial-mesenchymal transformation (EMT) and apoptosis specifically in K-Ras-dependent cells. These findings indicate that epithelial differentiation and tumor cell viability are associated, and that EMT regulators in "K-Ras-addicted" cancers represent candidate therapeutic targets.
引用
收藏
页码:489 / 500
页数:12
相关论文
共 42 条
  • [1] Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition
    Acevedo, Victor D.
    Gangula, Rama D.
    Freeman, Kevin W.
    Li, Rile
    Zhang, Youngyou
    Wang, Fen
    Ayala, Gustavo E.
    Peterson, Leif E.
    Ittmann, Michael
    Spencer, David M.
    [J]. CANCER CELL, 2007, 12 (06) : 559 - 571
  • [2] Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
    Aguirre, AJ
    Bardeesy, N
    Sinha, M
    Lopez, L
    Tuveson, DA
    Horner, J
    Redston, MS
    DePinho, RA
    [J]. GENES & DEVELOPMENT, 2003, 17 (24) : 3112 - 3126
  • [3] High-resolution characterization of the pancreatic adenocarcinoma genome
    Aguirre, AJ
    Brennan, C
    Bailey, G
    Sinha, R
    Feng, B
    Leo, C
    Zhang, YY
    Zhang, J
    Gans, JD
    Bardeesy, N
    Cauwels, C
    Cordon-Cardo, C
    Redston, MS
    DePinho, RA
    Chin, L
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (24) : 9067 - 9072
  • [4] Use of retrovirus expression of interfering RNA to determine the contribution of activated K-ras and ras effector expression to human tumor cell growth
    Baines, Antonio T.
    Lim, Kian-Huat
    Shields, Janiel M.
    Lambert, John M.
    Counter, Christopher M.
    Der, Channing J.
    Cox, Adrienne D.
    [J]. REGULATORS AND EFFECTORS OF SMALL GTPASES: RAS FAMILY, 2006, 407 : 556 - +
  • [5] Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer
    Bardeesy, Nabeel
    Cheng, Kuang-hung
    Berger, Justin H.
    Chu, Gerald C.
    Pahler, Jessica
    Olson, Peter
    Hezel, Aram F.
    Horner, James
    Lauwers, Gregory Y.
    Hanahan, Douglas
    DePinho, Ronald A.
    [J]. GENES & DEVELOPMENT, 2006, 20 (22) : 3130 - 3146
  • [6] Gene-expression profiles predict survival of patients with lung adenocarcinoma
    Beer, DG
    Kardia, SLR
    Huang, CC
    Giordano, TJ
    Levin, AM
    Misek, DE
    Lin, L
    Chen, GA
    Gharib, TG
    Thomas, DG
    Lizyness, ML
    Kuick, R
    Hayasaka, S
    Taylor, JMG
    Iannettoni, MD
    Orringer, MB
    Hanash, S
    [J]. NATURE MEDICINE, 2002, 8 (08) : 816 - 824
  • [7] Oncogenic pathway signatures in human cancers as a guide to targeted therapies
    Bild, AH
    Yao, G
    Chang, JT
    Wang, QL
    Potti, A
    Chasse, D
    Joshi, MB
    Harpole, D
    Lancaster, JM
    Berchuck, A
    Olson, JA
    Marks, JR
    Dressman, HK
    West, M
    Nevins, JR
    [J]. NATURE, 2006, 439 (7074) : 353 - 357
  • [8] A comparison of normalization methods for high density oligonucleotide array data based on variance and bias
    Bolstad, BM
    Irizarry, RA
    Åstrand, M
    Speed, TP
    [J]. BIOINFORMATICS, 2003, 19 (02) : 185 - 193
  • [9] R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation
    Braselmann, Sylvia
    Taylor, Vanessa
    Zhao, Haoran
    Wang, Su
    Sylvain, Catherine
    Baluom, Muhammad
    Qu, Kunbin
    Herlaar, Ellen
    Lau, Angela
    Young, Chi
    Wong, Brian R.
    Lovell, Scott
    Sun, Thomas
    Park, Gary
    Argade, Ankush
    Jurcevic, Stipo
    Pine, Polly
    Singh, Rajinder
    Grossbard, Elliott B.
    Payan, Donald G.
    Masuda, Esteban S.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (03) : 998 - 1008
  • [10] Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines
    Coldren, Christopher D.
    Helfrich, Barbara A.
    Witta, Samir E.
    Sugita, Michio
    Lapadat, Razvan
    Zeng, Chan
    Baron, Anna
    Franklin, Wilbur A.
    Hirsch, Fred R.
    Geraci, Mark W.
    Bunn, Paul A., Jr.
    [J]. MOLECULAR CANCER RESEARCH, 2006, 4 (08) : 521 - 528